Online inquiry

IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3309MR)

This product GTTS-WQ3309MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets lukG&lukH gene. The antibody can be applied in Staphylococcal infections research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq WP_000791407.1; WP_000791411.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 59700810; 59700811
UniProt ID A0A390DBJ6; A0A390DBJ6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ3309MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5868MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CIFN
GTTS-WQ759MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AB0024
GTTS-WQ99MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 1121B
GTTS-WQ10584MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-3127804
GTTS-WQ12189MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MORAb-022
GTTS-WQ5819MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ15177MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA T1h
GTTS-WQ6017MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 1275
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW